DavidSSapersteinMD

Neurology • Scottsdale, AZ

Neuromuscular Medicine, Neurophysiology

Phoenix Neurological Associates

Join to view full profile

Dr. Saperstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Saperstein's full profile

Already have an account?

Office
7054 E Cochise Road
Ste B230
Scottsdale, AZ 85253
Phone+1 602-900-9404

Fax+1 602-903-6587

Summary

I am a board-certified neurologist and neuromuscular specialist focused on the diagnosis and management of disorders of nerve, muscle and autonomic nervous system, as well as Ehlers-Danlos Syndrome.

Education & Training

University of Texas Southwestern Medical CenterFellowship, Clinical Neurophysiology, 1997 - 1998
San Antonio Uniformed Services Health Education ConsortiumResidency, Neurology, 1997
San Antonio Uniformed Services Health Education ConsortiumInternship, Internal Medicine, 1992 - 1993
Boston University School of MedicineClass of 1992

Certifications & Licensure

AZ State Medical License 2005 - 2026
TX State Medical License 1997 - 2025
MN State Medical License 2019 - 2021
NV State Medical License 2019 - 2021
IL State Medical License 2019 - 2020
PA State Medical License 1996 - 1998
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Clinical Neurophysiology
American Board of Psychiatry and Neurology Neuromuscular Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Intergy EHR, Vitera Healthcare Solutions, LLC, 2013

Clinical Trials

Efficacy of Methotrexate in Myasthenia Gravis Start of enrollment: 2009 Apr 01
Completed
Phase 2
Combination Therapy in Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2008 Jun 01
Completed
Phase 1, Phase 2
Safety Study of High Doses of Zinc in ALS Patients Start of enrollment: 2010 Oct 01
Completed
Phase 1, Phase 2
International Guillain-Barré Syndrome Outcome Study Start of enrollment: 2012 May 01
Active, not recruiting
Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2013 Nov 21
Completed
Phase 2
Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Start of enrollment: 2015 Aug 01
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

287 citations
Clinical spectrum of chronic acquired demyelinating polyneuropathies.
David Saperstein, Jonathan S. Katz, Anthony A. Amato, Richard J. Barohn
Muscle & Nerve. 2001-03-01
55 citations
Diagnosis of mast cell activation syndrome: a global "consensus-2".
Lawrence B. Afrin, Mary B. Ackerley, Linda S. Bluestein, Joseph H. Brewer, Jill B Brook
Diagnosis. 2021-05-01
55 citations
Phase I clinical trial of safety of L-serine for ALS patients
Todd Levine, Robert G. Miller, Walter G. Bradley, Dan H. Moore, David Saperstein
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2017-01-02

Press Mentions

RE Pharmacy Announces New Infusion Center in Phoenix, AZOctober 3rd, 2019